Pipeline and spin-off potential •         Pipeline: Glucon has a larger version of the product in preclinical studies and clinical trials suppose to begin in the second half of 2005. The larger product will be marketed to physicians and is a precursor to a miniaturized version that will provide continuous glucose monitoring for consumers.
•          The company does not have any other devices in development at the time.
•         Spin-off potential: Glucon's photoacoustics technology is also applicable to measuring levels of hemoglobin, triglyceride and ethanol levels but Glucon will remain focused on the diabetes market •         Conclusion: at the moment, the company concentrate mainly on one area, which make it relatively high risk מצגת בת 6 שקופיות